Full Press Release Details
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The company has no obligation to provide any updates to these forward-looking statements, even if its expectations change, whether as a result of new information, future events or otherwise, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this presentation should be considered in conjunction with a review of the company's filings with the SEC including the information in the company's Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIALCONDITION AND RESULTS OF OPERATIONS. Safe Harbor Statement
Follow Patient with Regularly Scheduled Office Visits NO Is Patient <21 Weeks Gestation? Does Patient Meet PreTRM Testing Criteria*? Provider Orders PreTRM Blood Test Drawn at 18 Weeks to 20 Weeks-6 Days Results Sent to Provider Office Within 5 Days Do Test Results Show Higher Risk for Spontaneous Preterm Birth? NO NO Patient Presents to Prenatal Care Provider This is an example clinical protocol from a large integrated system. Sera does not give medical advice or endorse any specific protocol for any specific practice or patient. You should customize this document to fit your practice and its treatment protocols. CARE MANAGEMENT Refer patient to care management services for weekly phone outreach & assessment PROGESTERONE SUPPLEMENTATION Start daily vaginal progesterone 200mg TARGETED INTERVENTION BUNDLE LOW-DOSE ASPIRIN Start LDA 81mg/day until 36 Weeks YES PreTRM identifies those who may benefit most from targeted preterm birth interventions AS A RISK STRATIFICATION BIOMARKER TEST PreTRM TESTING CRITERIA Single Fetus No History of Preterm Birth Unknown or Normal Cervical Length Intact Membranes No Signs of Preterm Labor
Q3 2024 earnings release highlights balance of ~$75M cash on Sera's balance sheet Source: Sera Q3 2024 10Q. SERA'S STRONG BALANCE SHEET Sera cash position extends well into 2027 to support reaching seminal revenue inflection point ~$75M With <$30M annual operating spend, strong balance sheet allows Sera to push full steam ahead on Commercialization to reach seminal inflection point